Ratings Teladoc Health, Inc.

Equities

TDOC

US87918A1051

Market Closed - Nyse Other stock markets 21:00:02 26/04/2024 BST			Pre-market 12:13:23
13.01 ^USD	-2.40%		12.92	-0.65%

04-26	UBS Adjusts Teladoc Price Target to $16 From $20, Maintains Neutral Rating	MT
04-26	Oppenheimer Cuts Teladoc's Price Target to $21 From $26, Maintains Outperform Rating	MT

Summary

The company presents an interesting fundamental situation from a short-term investment perspective.

Strengths

With regards to fundamentals, the enterprise value to sales ratio is at 0.94 for the current period. Therefore, the company is undervalued.
The company appears to be poorly valued given its net asset value.
Given the positive cash flows generated by its business, the company's valuation level is an asset.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

According to forecast, a sluggish sales growth is expected for the next fiscal years.
Low profitability weakens the company.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
TELADOC HEALTH, INC.	-39.63%	2.21B		D+
HIMS & HERS HEALTH, INC.	+40.45%	2.68B		-
TALKSPACE, INC.	+22.83%	527M		-
QDM INTERNATIONAL INC.	+42.77%	467M	-	-
AMERICAN WELL CORPORATION	-64.56%	157M		C-
SHL TELEMEDICINE LTD.	-31.65%	85.12M	-	C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes